Scientists at Scripps Research have developed a urine diagnostic to detect the parasitic worms that cause river blindness, also called onchocerciasis, a tropical disease that afflicts 18 to 120 million people worldwide.
Described in the journal ACS Infectious Diseases, the new, non-invasive test may provide an inexpensive method of determining in real time whether a person has an infection, which would give public health officials and doctors critical information for tracking outbreaks and treating current infections.
“River blindness affects individuals both in Africa and Latin America, and because many of these endemic regions are difficult to access, what is needed in the field is an inexpensive point-of-care means to monitor the disease,” says Kim Janda, PhD, the Ely R. Callaway Jr. Professor of Chemistry and member of the Skaggs Institute for Chemical Biology at Scripps Research.
River blindness is a filarial disease, like elephantiasis, and occurs when the parasitic worm Onchocerca volvulus takes up residence in the skin. Adult worms pump out babies (microfilaria) at an alarming rate, which are ultimately re-spread by blackfly bites. The microfilariae can migrate to the eye and die, releasing toxins and causing inflammation. People with the disease will slowly go blind without medical intervention.
Janda says onchocerciasis monitoring and evaluation are especially necessary steps for people leading elimination efforts. To know if these efforts are working, doctors need to be able to show when disease transmission has been interrupted. The current gold standard for detecting the parasitic worms is a “skin snip” biopsy. However, snips are generally insensitive indicators of infection, and the sensitivity of the skin snip decreases as the density of microfilaria in the skin decreases. Other tests cannot distinguish between past and current infections.
Currently, onchocerciasis elimination programs rely primarily on mass drug administration of the therapy Ivermectin to suppress and eventually eliminate transmission of Onchocerca volvulus. Yet, without a means to evaluate if an infection is ongoing, it’s hard to assess if prevention efforts are working—and if it’s safe for people to stop taking medication.
The new lateral flow assay took over 10 years to develop, but it is now ready for manufacturing and testing in the field. The key to the assay’s success was in the making of designer antibodies to detect a unique biomarker that only shows up when a human host has metabolized a worm neurotransmitter called tyramine. Humans then secrete this biomarker in urine.
A negative on the “dipstick” test shows a colored line in the test. Got the parasite? The test would show no lines.
Unlike the skin snip biopsy, Janda says this non-invasive test is the first to use a metabolite produced by adult worms. Moreover, the dipstick’s inexpensive design, coupled with smartphone apps, would offer automatic image processing, which ultimately could translate to address critical gaps in the surveillance and treatment of river blindness.
The Latest on: River blindness
via Google News
The Latest on: River blindness
- Eastern Sudan's Gallabat area declared free of river blindness on November 18, 2018 at 1:47 pm
KHARTOUM, Nov. 18 (Xinhua) -- Sudan's Federal Ministry of Health on Sunday declared Gallabat area in eastern Sudan's Qadarif State, on the border with Ethiopia, free of river blindness. "Sudan has man... […]
- Basic research in fruit flies leads to potential drug for diseases afflicting millions on July 12, 2018 at 11:37 am
Filarial nematodes, parasitic worms that cause river blindness and elephantiasis, are dependent on Wolbachia bacteria that infect the cells of the worms and are responsible for much of the pathology o... […]
- Aussie nonprofit gains FDA approval, along with PRV for river blindness drug on June 18, 2018 at 5:00 pm
PERTH, Australia – Melbourne-based Medicines Development for Global Health (MDGH) became the first not for profit company to register a drug through the FDA's tropical disease priority review program. […]
- Ugandan doctor co-finds new River blindness drug on June 17, 2018 at 5:00 pm
Born in Zombo District, Dr Nyathirombo, 52, is an eye specialist and lecturer in the Department of Ophthalmology at Gulu University. He previously lectured at Makerere University after working at Arua ... […]
- U.S. FDA Approves Moxidectin For The Treatment Of River Blindness on June 13, 2018 at 3:02 pm
NOT-FOR-PROFIT BIOPHARMACEUTICAL COMPANY RECEIVES FDA APPROVAL FOR A NEW RIVER BLINDNESS TREATMENT. MELBOURNE, Australia, GENEVA, and NEW YORK, June 13, 2018 /PRNewswire/ -- Medicines Development for ... […]
- U.S. FDA Approves Moxidectin For The Treatment Of River Blindness on June 12, 2018 at 5:00 pm
MELBOURNE, Australia, GENEVA, and NEW YORK, June 13, 2018 /PRNewswire/ -- Medicines Development for Global Health (MDGH) and the World Health Organisation Special Programme for Research and Training i... […]
- river-blindness7_1350 on April 9, 2018 at 5:00 pm
These nematodes can complicate treatment for river blindness. (Brian Rinker for KHN) Copy HTML We encourage organizations to republish our content, free of charge. Here’s what we ask: You must cre... […]
- Why aren’t we curing the world’s most curable diseases? on November 8, 2017 at 10:12 am
Once upon a time, the world suffered. In 1987, 20 million people across the world were plagued by a debilitating, painful and potentially blinding disease called river blindness. This parasitic infect... […]
via Bing News